10h agoMarketWatchBULLISH 74Earnings
Archived explainer. For the current picture see today's ETON page.
Why Is ETON PHARMACEUTICALS (ETON) Stock Up Today?
By the Top Tier Newswire AI Desk · November 6, 2026 at 2:48 PM ET · reviewed against 16 wire stories
ETON PHARMACEUTICALS (ETON) is up +21.31% in the latest session. Our newswire has captured 16 stories on ETON across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Eton Pharmaceuticals shares surged 21.31% to close at $57.20, driven by a strong third quarter that saw revenue more than double year over year. The rare disease specialist also raised its full-year 2026 revenue guidance to over $175 million, signaling confidence in its upcoming product launches.
What Happened
The stock jumped after the company reported 158% revenue growth for the third quarter, significantly beating expectations. Management outlined a record margin profile and raised its outlook, citing strong demand for its existing portfolio. The company also confirmed a target launch date of April 2027 for its next-generation product, LIBERVANT.
Following the earnings release, several analysts upgraded their views on the stock. HC Wainwright & Co. maintained a Buy rating and raised its price target to $80. Canaccord also maintained a Buy rating, lifting its target from $68 to $80. Craig-Hallum raised its price target from $78 to $82. These moves reflect growing confidence in the company's ability to execute on its pipeline.
What The Data Shows
The stock opened at $56.42, a 19.7% gap up from the prior close of $47.15. Intraday trading saw a session high of $58.96 at 8:50 AM ET and a low of $51.82 at 10:00 AM ET. Volume reached 0.7 million shares, which is 1.2 times the three-month daily average.
Fundamentals show a market cap of $1.4 billion with a P/E ratio of 110.2. Trailing twelve-month revenue grew 81.5%, and the net margin stands at 12.0%. The stock has a beta of 0.83 and a 52-week range of $14.27 to $66.37. Over the last eight sessions, the stock had declined 7.8% from $51.16 to $47.15 before this move. Recent insider activity includes three sales totaling $10.7 million in the last 90 days, with no buys recorded.
What To Watch
Investors will monitor the company's progress toward the April 2027 launch of LIBERVANT. The stock's ability to sustain its new valuation levels following the guidance hike will be a key focus for analysts and traders in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ETON by the numbers
Last: $57.20Session: +21.31%7 sessions: -7.84%Coverage: 16 stories / 9 sourcesAI sentiment: 65/100 (bullish)Mkt cap: $1.4BP/E: 110.252w: $14.27 to $66.37
The headlines behind the move
11h agoGuruFocusBULLISH 63Analyst
ETON Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $80
On October 14, 2026, Eton Pharmaceuticals (ETON) received a "Buy" rating from HC Wainwright & Co. analyst Swayampakula Ramakanth. The firm has maintained its ov
11h agoThe FlyBULLISH 63Analyst
Eton Pharmaceuticals price target raised to $82 from $78 at Craig-Hallum
11h agoSeeking AlphaBULLISH 74Earnings
Eton Pharma jumps after Q3 beat and guidance hike
Eton Pharmaceuticals (ETON) stock surged after strong Q3 earnings, 158% revenue growth, and a raised outlook. Read more here.
13h agoThe FlyBULLISH 64Analyst
Eton Pharmaceuticals price target raised to $80 from $68 at Canaccord
18h agoThe Motley FoolBULLISH 74Earnings
Eton Pharma (ETON) Q3 2026 Earnings Call Transcript
Rare disease specialist posts record margins and raises outlook.
23h agoSeeking AlphaBULLISH 74Earnings
Eton outlines more than $175M 2026 revenue guidance as it targets an April 2027 LIBERVANT launch
Eton Pharmaceuticals Q3 2026 earnings: revenue surged 158%, guidance rose above $175M, and LIBERVANT/FDA catalysts add upside.
23h agoSeeking AlphaNEUTRAL 50Earnings
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call November 5, 2026 4:30 PM ESTCompany ParticipantsDavid Krempa - Chief Business OfficerSean Brynjelsen...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ETON: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ETON move explainers: 2026-11-06 · 2026-10-14